SECURE-CODE-WARRIOR
2.6.2022 14:02:13 CEST | Business Wire | Press release
Secure Code Warrior , the global, developer-driven security leader, today announced an exciting addition to the Okta Integration Network. Okta , the leading independent provider of identity, and Secure Code Warrior collaborated to deliver a new solution - the Secure Code Warrior (SCW) Connector for Okta Workflows, which enables organizations and developers to write secure code from the start of the software development lifecycle (SDLC).
Applying a security-first mindset, organizations can design an identity workflow that protects builds from the beginning of the life cycle, giving organizations the flexibility to only provide GitHub repo access to security proficient developers. This helps organizations promote a security first culture while the SCW Learning Platform enables developers to meet these standards and requirements. Organizations have implemented this solution across their application, security and engineering teams to provide this additional layer of security.
Preventing insecure code and ensuring better access control during software development remains a significant need for industries across all verticals. Meanwhile, developers recognize the importance of delivering secure software applications but face competing priorities. According to SCW’s recently released “The State of Developer-Driven Security Survey, 2022” , 67% knowingly left vulnerabilities and exploits in their code, with a lack of time and a cohesive approach cited as the two main barriers to the adoption of secure coding practices.
“This new solution will help organizations reduce the risk of developers committing insecure code by ensuring that employees are up to date on the latest vulnerabilities and secure coding techniques. Through our work together with Okta on a security proficiency check, AppSec Managers can be confident that the team is committing secure code without moving developers out of their workflow. Now, leaders can focus on broad strategic efforts to improve the organization’s security posture without sacrificing quality or time.” said Pieter Danhieux, Co-founder and CEO, Secure Code Warrior.
“Okta Workflows provides a no-code, low-code approach to automating identity-centric processes at scale. As an early adopter of Workflows Connector Builder, we are excited to have the new Secure Code Warrior connector in the Okta Integration Network, which goes beyond SSO and provisioning to support advanced integration flows. Developers can be confident that their secure code knowledge is up to date and relevant to the code they are committing” said David Shackelford, Senior Director, Okta.
The Secure Code Warrior Connector for Okta Workflows utilizes key components of both companies’ technology platforms to benefit organizations and developers alike:
- Pre-configured actions enable developer teams to quickly build the desired workflows in a no-code/low code environment, without the hassle of getting into the complexities of API calls.
- Once the workflow is ready, it will run automatically and can be customized for frequency.
- Secure Code Warrior’s Learning Platform provides information on the developers’ assessment score and course completion status, giving teams the insights to determine their security skills when writing code.
- Organizations have the flexibility to only allow GitHub repo access to security proficient developers
Creating and automating secure developer workflows is now easier than ever thanks to this new industry solution from Secure Code Warrior and Okta. The Secure Code Warrior Connector for Okta Workflows is available at https://help.okta.com/wf/en-us/Content/Topics/Workflows/connector-reference/securecodewarrior/securecodewarrior.htm .
To learn more, visit www.securecodewarrior.com/blog/scw-connector-for-okta-workflows .
About Secure Code Warrior
Secure Code Warrior builds a culture of security-driven developers by giving them the skills to code securely. Our flagship Learning Platform delivers relevant skills-based pathways, hands-on missions, and contextual tools for developers to rapidly learn, build, and apply their skills to write secure code at speed. Established in 2015, Secure Code Warrior has become a critical component for over 450 enterprises including leading financial services, retail, and global technology companies across the world. Visit: www.securecodewarrior.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005007/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom